Skip to content

CKD mineral and bone disorder

TL;DR — CKD-MBD links biochemical abnormalities, bone turnover/mineralisation, fracture and vascular or valvular calcification; no single phosphate or PTH value defines the whole disorder (Ketteler 2017, PMID 28646995). Observational associations are strong, but randomized evidence that correcting a biochemical target improves survival is sparse. EVOLVE did not meet its unadjusted primary cardiovascular endpoint for cinacalcet in dialysis (EVOLVE Trial Investigators 2012, PMID 23121374). A systematic review of 77 trials (63 randomized; 6,898 participants; median sample size 50, median duration 12 months) found the data on attenuating vascular calcification itself insufficient or conflicting: magnesium and sodium thiosulfate were the only consistently positive interventions, phosphate binders, dialysate calcium, vitamin K, calcimimetics and antiresorptives were conflicting or inconclusive, and vitamin D and statins showed no attenuation (Xu 2022, PMID 35232774). Treatment should therefore distinguish biochemical control from proven clinical-outcome modification.

Integrated phenotype

Phosphate retention, altered vitamin D metabolism, hypocalcaemia, FGF23 and secondary hyperparathyroidism interact with bone and vasculature. Trends are more informative than isolated values (Ketteler 2017, PMID 28646995).

Bone disease

Turnover can be high or low; the same PTH concentration does not identify histology reliably. Fracture risk also reflects age, falls and conventional osteoporosis.

Vascular calcification

Calcification predicts risk but is not automatically a validated treatment surrogate. Across 77 trials the median sample was 50 participants and median duration 12 months, and interventions differed in imaging site, score and duration — magnesium and sodium thiosulfate looked most promising but only in small, short studies (Xu 2022, PMID 35232774).

Phosphate lowering

Dietary restriction and binders lower phosphate, yet patient-important outcome evidence in non-dialysis CKD remains limited. Pill burden and nutrition are counterweights.

Cinacalcet

EVOLVE randomized 3,883 haemodialysis patients; the primary composite was not significantly reduced in the unadjusted intention-to-treat analysis (EVOLVE Trial Investigators 2012, PMID 23121374).

Guideline logic

KDIGO 2017 moved toward serial, integrated interpretation and away from treating every isolated biochemical abnormality (Ketteler 2017, PMID 28646995).

Marker–intervention–outcome map

Target Common intervention What is established What is not established
Phosphate Diet and binders Biochemical lowering Consistent survival or fracture benefit in non-dialysis CKD
PTH Vitamin D analogues, calcimimetics, surgery PTH lowering One target valid across turnover states
Vitamin D Native or active vitamin D Corrects selected biochemical abnormalities Universal cardiovascular benefit
Bone turnover Cause-specific therapy Biopsy is reference phenotype in selected cases Reliable classification by one PTH value
Vascular calcification Binder, calcimimetic or other strategies Imaging change is measurable; magnesium and sodium thiosulfate attenuated it consistently That any of it changes patient-important outcomes; 77 trials, median n=50 and 12 months (Xu 2022, PMID 35232774)
Secondary hyperparathyroidism in dialysis Cinacalcet Biochemical effect Unadjusted EVOLVE primary outcome benefit (EVOLVE 2012, PMID 23121374)

Four negative trials define this field

CKD-MBD is unusual in nephrology: the biochemical abnormalities are strongly prognostic, and almost every attempt to correct them has failed to change outcomes.

Calcimimetics. EVOLVE randomized 3,883 haemodialysis patients with moderate-to-severe secondary hyperparathyroidism (median intact PTH 693 pg/mL, 10th–90th percentile 363–1,694) to cinacalcet or placebo on top of conventional therapy, following them up to 64 months. The primary composite — death, myocardial infarction, hospitalisation for unstable angina, heart failure or a peripheral vascular event — occurred in 938/1,948 (48.2%) versus 952/1,935 (49.2%), relative hazard 0.93 (95% CI 0.85–1.02; p = 0.11) in the unadjusted intention-to-treat analysis. Hypocalcaemia and gastrointestinal adverse events were significantly more frequent with cinacalcet (Chertow 2012, PMID 23121374). Median study-drug exposure differed between arms (21.2 versus 17.5 months), and the much-discussed age-adjusted analyses were not the prespecified primary result.

Phosphate binder choice. LANDMARK randomized 2,309 Japanese haemodialysis patients with hyperphosphataemia and at least one vascular-calcification risk factor (age ≥65, postmenopausal, or diabetes) across 273 facilities to lanthanum carbonate or calcium carbonate, titrated to phosphate 3.5–6.0 mg/dL, with blinded endpoint adjudication. After median 3.16 years, composite cardiovascular events occurred in 147/1,063 versus 134/1,072 — 4.80 versus 4.30 per 100 person-years; difference 0.50 (95% CI −0.57 to 1.56); HR 1.11 (0.88–1.41), p = 0.37 — with no significant difference in all-cause death (Ogata 2021, PMID 34003226). The trial was designed on the hypothesis that a non-calcium binder would reduce events; the point estimate went the other way.

The binder evidence base as a whole. The 2025 Cochrane update covers 134 studies and 20,913 adults, with 30 new studies added. Risk of bias was high or unclear across many methodological domains and the certainty of evidence was judged low or very low for the key outcomes of all-cause death, cardiovascular death, hypercalcaemia, nausea, constipation, serum phosphate and vascular calcification (Natale 2025, PMID 40576086). After more than a hundred randomized trials, this remains a field in which the certainty rating on mortality is low.

Active vitamin D. PRIMO randomized 227 patients with eGFR 15–60, mild-to-moderate left ventricular hypertrophy and preserved ejection fraction across 11 countries to oral paricalcitol 2 µg/day or placebo for 48 weeks. Paricalcitol reduced PTH within 4 weeks and held it in range, but the change in left ventricular mass index did not differ (paricalcitol +0.34 g/m^2.7, 95% CI −0.14 to 0.83; placebo −0.07, −0.55 to 0.42), nor did Doppler diastolic measures, while hypercalcaemia was more frequent with paricalcitol (Thadhani 2012, PMID 22337679).

Target Trial Biochemistry moved? Outcome moved?
PTH EVOLVE, n=3,883 (PMID 23121374) Yes No: HR 0.93 (0.85–1.02); more hypocalcaemia and GI events
Phosphate, binder class LANDMARK, n=2,309 (PMID 34003226) Both arms titrated to target No: HR 1.11 (0.88–1.41)
Phosphate, all binders Cochrane 2025, 134 studies, 20,913 adults (PMID 40576086) Yes Certainty low or very low for death and cardiovascular death
Left ventricular mass via vitamin D receptor PRIMO, n=227 (PMID 22337679) PTH suppressed within 4 weeks No: LVMI difference not significant; more hypercalcaemia

What the negative results collectively imply

Three readings are compatible with the data and the field has not chosen between them.

  1. Wrong target. PTH, phosphate and vitamin D receptor activation may be markers of the disordered state rather than the drivers of vascular and skeletal harm — in which case correcting them cannot help, and the strong observational associations are confounded by the severity of the underlying disease.
  2. Wrong timing. All four patient-important-outcome trials intervened in prevalent dialysis or advanced CKD, where vascular calcification is established. Biochemical trials exist earlier, but no trial has tested whether binder or calcimimetic therapy at G3 improves patient-important outcomes.
  3. Wrong endpoint or wrong dose. EVOLVE's exposure imbalance and LANDMARK's open-label titration in both arms leave room for a real effect obscured by trial conduct.

The practical consequence is that the biochemical targets in CKD-MBD guidelines are supported by prognostic association and by trials showing the biochemistry can be moved, not by trials showing that moving it helps — a distinction that the guidelines page treats as a class-of-evidence question.

Calciphylaxis: the complication where the evidence base is thinnest

Calciphylaxis (calcific uraemic arteriolopathy) is rare, predominantly seen in dialysis-treated kidney failure but also described at earlier CKD stages and with normal kidney function. A multidisciplinary review of the literature on risk factors, diagnosis and treatment of both uraemic and non-uraemic forms concluded explicitly that high-quality evidence for evaluation and management is lacking, attributing this to rare incidence, poorly understood pathogenesis and a relative absence of collaborative research; the recommendations offered are consensus-derived rather than trial-derived (Nigwekar 2015, PMID 25960299).

This is worth recording in a knowledge base rather than passed over, because it is the honest state of the field for a condition with high mortality: an entity defined largely by expert agreement, treated with agents (sodium thiosulfate among them) whose efficacy rests on case series, in a population where the underlying mineral disorder has itself resisted every randomized attempt at correction described above. The combination of a plausible mechanism, a devastating outcome and no controlled evidence is the pattern most likely to sustain ineffective practice indefinitely.

Decision and interpretation matrix

Dimension Question Guardrail
Diagnostic axis Cause + G category + A category Avoid treating eGFR as the diagnosis
Time axis Chronicity and trajectory Separate acute change from persistent disease
Risk axis Kidney failure + cardiovascular events + death Show competing events
Treatment axis Eligibility, absolute benefit, harm, burden Do not rank drugs by relative effect alone
Measurement axis Assay, equation, repeatability State what was actually measured
Equity axis Testing, referral, access, affordability Audit downstream care, not labels only
Patient axis Symptoms, function, life participation Include outcomes patients prioritize
Evidence axis RCT, cohort, model, guideline Do not collapse designs

Evidence ledger

This ledger makes the page’s evidentiary mix inspectable. It does not imply that every source answers every question.

PMID Record used Role and boundary
28646995 Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder Guideline Update. (Ketteler 2017, PMID 28646995) Guideline or commentary; recommendation evidence depends on its review.
23121374 Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. (EVOLVE Trial Investigators 2012, PMID 23121374) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
35232774 Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials. (Xu 2022, PMID 35232774) Synthesis; heterogeneity and included-study definitions constrain transport.
38490803 KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. (KDIGO CKD Work Group 2024, PMID 38490803) Guideline or commentary; recommendation evidence depends on its review.
38519239 Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. (Levin 2024, PMID 38519239) Guideline or commentary; recommendation evidence depends on its review.
32061315 Global, regional, and national burden of chronic kidney disease, 1990-2017. (GBD CKD Collaboration 2020, PMID 32061315) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
22038337 A population-based approach for the definition of chronic kidney disease: CKD Prognosis Consortium. (Cirillo 2012, PMID 22038337) Synthesis; heterogeneity and included-study definitions constrain transport.
23243116 Cohort profile: the chronic kidney disease prognosis consortium. (Matsushita 2013, PMID 23243116) Observational or conceptual evidence; association is not treatment effect.
37787795 Estimated GFR, Albuminuria, and Adverse Outcomes: individual-participant data meta-analysis. (CKD Prognosis Consortium 2023, PMID 37787795) Synthesis; heterogeneity and included-study definitions constrain transport.
30348535 Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities. (Inker 2019, PMID 30348535) Synthesis; heterogeneity and included-study definitions constrain transport.
34554658 New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. (Inker 2021, PMID 34554658) Observational or conceptual evidence; association is not treatment effect.
34563581 A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. (Delgado 2022, PMID 34563581) Guideline or commentary; recommendation evidence depends on its review.
26757465 Multinational assessment of equations predicting kidney failure. (Tangri 2016, PMID 26757465) Synthesis; heterogeneity and included-study definitions constrain transport.
36857500 Kidney Failure Risk Equation evaluation with novel inputs in 59 cohorts. (Grams 2023, PMID 36857500) Observational or conceptual evidence; association is not treatment effect.
26028594 eGFR and albuminuria for prediction of cardiovascular outcomes: individual-participant meta-analysis. (Matsushita 2015, PMID 26028594) Synthesis; heterogeneity and included-study definitions constrain transport.
26564024 Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial. (Pun 2016, PMID 26564024) Intervention study; eligibility, comparator, endpoint and follow-up bound inference.
32753447 Cost-effectiveness analysis of cinacalcet for haemodialysis patients with secondary hyperparathyroidism based on EVOLVE. (Liu 2020, PMID 32753447) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
26265359 Cinacalcet and Clinical Outcomes in Dialysis. (Komaba 2015, PMID 26265359) Observational or conceptual evidence; association is not treatment effect.
26686794 Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. (Belozeroff 2015, PMID 26686794) Modelled projection; the estimate follows from the model inputs and assumptions, not from observed randomized follow-up.
30675420 KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD. (KDIGO CKD-MBD Update Work Group 2017, PMID 30675420) Guideline or commentary; recommendation evidence depends on its review.
39864017 Chronic kidney disease-mineral and bone disorder: conclusions from a KDIGO Controversies Conference. (Ketteler 2025, PMID 39864017) Guideline or commentary; recommendation evidence depends on its review.
30236082 Renal Association commentary on the KDIGO 2017 CKD-MBD guideline update. (Burton 2018, PMID 30236082) Guideline or commentary; recommendation evidence depends on its review.
30150095 Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients. (Beto 2019, PMID 30150095) Guideline or commentary; recommendation evidence depends on its review.
31890994 KDIGO CKD-MBD Guideline Update Implementation: Asia Summit Conference Report. (Wang 2019, PMID 31890994) Guideline or commentary; recommendation evidence depends on its review.
28941764 KDOQI US Commentary on the 2017 KDIGO CKD-MBD Guideline Update. (Isakova 2017, PMID 28941764) Guideline or commentary; recommendation evidence depends on its review.

What can and cannot be concluded

  • Risk associations do not by themselves establish that changing the marker changes risk.
  • A relative effect must be paired with baseline risk, follow-up and the exact endpoint.
  • Albuminuria, acute eGFR change, chronic eGFR slope and kidney failure are not interchangeable.
  • Subgroup consistency is not evidence that every subgroup had adequate power.
  • Guideline recommendations combine evidence with values, feasibility, cost and service capacity.
  • Older adults require competing-mortality and treatment-burden framing.
  • Dialysis and transplantation comparisons are vulnerable to eligibility and immortal-time bias.
  • Modelled lifetime benefit is not a randomized observed benefit.
  • A biochemical response without a patient-important outcome remains a surrogate result.
  • This page is research synthesis, not individualized medical advice.

Research-design checklist

  • Define CKD cause, G category, A category and chronicity at baseline.
  • Report the creatinine or cystatin C equation and laboratory calibration.
  • Prespecify acute and chronic eGFR slopes when haemodynamic effects are expected.
  • Keep sustained GFR decline, kidney failure and replacement therapy separable.
  • Report absolute event risks, follow-up and confidence intervals with relative effects.
  • Treat death as a competing event where it can preclude kidney failure.
  • Measure hyperkalaemia, acute kidney injury and treatment discontinuation consistently.
  • Include symptoms, function, life participation and treatment burden.
  • Describe background RAS, SGLT2, MRA and GLP-1 therapy explicitly.
  • Prespecify albuminuria and cause strata without over-reading underpowered interactions.
  • Record screening, prescribing, persistence and monitoring as separate implementation steps.
  • Report representation, access and affordability variables needed for equity analysis.

Open questions

  • What outcome would validate phosphate or vascular calcification as a treatment target? EVOLVE was neutral on its unadjusted primary endpoint and the calcification trial literature is small, short and conflicting (EVOLVE Trial Investigators 2012, PMID 23121374) (Xu 2022, PMID 35232774). → OQ-14
  • Do the magnesium and sodium thiosulfate signals survive an adequately powered, longer trial with a patient-important endpoint (Xu 2022, PMID 35232774)?
  • Can bone turnover be classified reliably enough without biopsy to direct PTH-lowering therapy? One PTH value does not identify histology (Ketteler 2017, PMID 28646995).

  • Does phosphate lowering in non-dialysis CKD change fracture or survival, or only the laboratory value?

  • Is CKD-MBD biochemistry a driver of harm or a marker of disease severity? Cinacalcet (PMID 23121374), binder class (PMID 34003226) and active vitamin D (PMID 22337679) all moved the biochemistry without moving outcomes.

  • Would earlier intervention work? Patient-important-outcome trials have enrolled prevalent dialysis or advanced CKD, after vascular calcification is established; earlier-stage biochemical trials do not show whether targeting phosphate or PTH at G3 improves clinical outcomes.

  • After 134 randomized trials and 20,913 participants, why is the certainty of evidence for phosphate binders on death still low or very low (Natale 2025, PMID 40576086), and what trial design would raise it?

  • Can calciphylaxis be studied in a controlled way at all, given rarity and mortality, and what registry or platform design would generate the evidence its consensus recommendations currently substitute for (Nigwekar 2015, PMID 25960299)?

References

  1. Ketteler et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder Guideline Update. Kidney Int. 2017;92(1):26-36. PMID 28646995
  2. EVOLVE Trial Investigators et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482-2494. PMID 23121374
  3. Xu et al. Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials. J Am Soc Nephrol. 2022;33(5):1011-1032. PMID 35232774
  4. KDIGO CKD Work Group et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. PMID 38490803
  5. Levin et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. PMID 38519239
  6. GBD CKD Collaboration et al. Global, regional, and national burden of chronic kidney disease, 1990-2017. Lancet. 2020;395(10225):709-733. PMID 32061315
  7. Cirillo et al. A population-based approach for the definition of chronic kidney disease: CKD Prognosis Consortium. J Nephrol. 2012;25(1):7-12. PMID 22038337
  8. Matsushita et al. Cohort profile: the chronic kidney disease prognosis consortium. Int J Epidemiol. 2013;42(6):1660-1668. PMID 23243116
  9. CKD Prognosis Consortium et al. Estimated GFR, Albuminuria, and Adverse Outcomes: individual-participant data meta-analysis. JAMA. 2023;330(13):1266-1277. PMID 37787795
  10. Inker et al. Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities. Am J Kidney Dis. 2019;73(2):206-217. PMID 30348535
  11. Inker et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-1749. PMID 34554658
  12. Delgado et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. Am J Kidney Dis. 2022;79(2):268-288.e1. PMID 34563581
  13. Tangri et al. Multinational assessment of equations predicting kidney failure. JAMA. 2016;315(2):164-174. PMID 26757465
  14. Grams et al. Kidney Failure Risk Equation evaluation with novel inputs in 59 cohorts. J Am Soc Nephrol. 2023;34(3):482-494. PMID 36857500
  15. Matsushita et al. eGFR and albuminuria for prediction of cardiovascular outcomes: individual-participant meta-analysis. Lancet Diabetes Endocrinol. 2015;3(7):514-525. PMID 26028594
  16. Pun et al. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial. Hemodial Int. 2016;20(3):421-431. PMID 26564024
  17. Liu et al. Cost-effectiveness analysis of cinacalcet for haemodialysis patients with secondary hyperparathyroidism based on EVOLVE. BMJ Open. 2020;10(8):e034123. PMID 32753447
  18. Komaba et al. Cinacalcet and Clinical Outcomes in Dialysis. Semin Dial. 2015;28(6):594-603. PMID 26265359
  19. Belozeroff et al. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value Health. 2015;18(8):1079-1087. PMID 26686794
  20. KDIGO CKD-MBD Update Work Group et al. KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD. Kidney Int Suppl (2011). 2017;7(1):1-59. PMID 30675420
  21. Ketteler et al. Chronic kidney disease-mineral and bone disorder: conclusions from a KDIGO Controversies Conference. Kidney Int. 2025;107(3):405-423. PMID 39864017
  22. Burton et al. Renal Association commentary on the KDIGO 2017 CKD-MBD guideline update. BMC Nephrol. 2018;19(1):240. PMID 30236082
  23. Beto et al. Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients. J Ren Nutr. 2019;29(1):2-15. PMID 30150095
  24. Wang et al. KDIGO CKD-MBD Guideline Update Implementation: Asia Summit Conference Report. Kidney Int Rep. 2019;4(11):1523-1537. PMID 31890994
  25. Isakova et al. KDOQI US Commentary on the 2017 KDIGO CKD-MBD Guideline Update. Am J Kidney Dis. 2017;70(6):737-751. PMID 28941764
  26. Ogata H, et al. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial. JAMA. 2021;325(19):1946-1954. PMID 34003226
  27. Natale P, et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2025;6(6):CD006023. PMID 40576086
  28. Thadhani R, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA. 2012;307(7):674-684. PMID 22337679
  29. Nigwekar SU, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133-146. PMID 25960299